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Available online xxxxThe transition from single seizures to status epilepticus (SE) is associated with malaptive trafﬁcking of synaptic
gamma-aminobutyric acid (GABAA) and glutamate receptors. The receptor trafﬁcking hypothesis proposes that
these changes are key events in the development of pharmacoresistance to antiepileptic drugs (AEDs) during
SE, and that blocking their expression will help control drug-refractory SE (RSE).
We tested this hypothesis in a model of SE induced by very high-dose lithium and pilocarpine (RSE), and in a
model of SE inducedby sc soman. Bothmodels are refractory to benzodiazepineswhen treated40min after seizure
onset. Our treatments aimed to correct the loss of inhibition because of SE-associated internalization of synaptic
GABAA receptors (GABAAR), using an allosteric GABAAR modulator, sometimes supplemented by an AED acting
at a nonbenzodiazepine site. At the same time, we reduced excitation because of increased synaptic localization
of NMDA and AMPA (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and N-methyl-D-aspartate) recep-
tors (NMDAR, AMPAR (?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, N-methyl-D-aspartate
receptors)) with an NMDAR channel blocker, since AMPAR changes are NMDAR-dependent.
Treatment of RSE with combinations of the GABAAR allosteric modulatorsmidazolam or diazepam and the NMDAR
antagonists dizocilpine or ketamine terminated RSE unresponsive to high-dose monotherapy. It also reduced RSE-
associated neuronal injury, spatial memory deﬁcits, and the occurrence of spontaneous recurrent seizures (SRS),
tested several weeks after SE. Treatment of soman-induced SE also reduced seizures, behavioral deﬁcits, and
epileptogenesis. Addition of an AED further improved seizure outcome in both models. Three-dimensional
isobologramsdemonstrated positive cooperativity betweenmidazolam, ketamine, and valproate,without any inter-
action between the toxicity of these drugs, so that the therapeutic index was increased by combination therapy.
The midazolam–ketamine–valproate combination based on the receptor trafﬁcking hypothesis was far more ef-
fective in stopping RSE than the midazolam–fosphenytoin–valproate combination inspired from clinical guide-
lines for the treatment of SE. Furthermore, sequential administration of midazolam, ketamine, and valproate
was far less effective than simultaneous treatment with the same drugs at the same dose.
These data suggest that treatment of RSE should be based at least in part on its pathophysiology. The search for a
better treatment should focus on the cause of pharmacoresistance, which is loss of synaptic GABAAR and gain of
synaptic glutamate receptors. Both need to be treated. Monotherapy addresses only half the problem. Improved
pharmacokinetics will not help pharmacoresistance because of loss of receptors. Waiting for one drug to fail be-
fore giving the second drugs gives pharmacoresistance time to develop. Future clinical trials should consider
treating both the failure of inhibition and the runaway excitation which characterize RSE, and should include
an early polytherapy arm.
Published by Elsevier Inc.Keywords:
Epilepsy
Status epilepticus
Acute seizures
Pharmacoresistance
PolytherapyGreater Los Angeles Healthcare
90073, USA.
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. No other uses without permission. C1. Introduction: the receptor trafﬁcking hypothesis of seizure-
induced pharmacoresistance
Many drugs are now available to treat status epilepticus (SE). Most
of them are effective when given early in the course of SE [1]. As aerapy for benzodiazepine-refractory status epilepticus, Epilepsy & Be-
 HEALTHCARE SYSTEM from ClinicalKey.com by Elsevier on November 09, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
2 J. Niquet et al. / Epilepsy & Behavior xxx (xxxx) xxxmatter of fact, a fewminutes' gain in delivering benzodiazepines during
early SE results in a measurable difference in outcome [2]. However,
when treatment is delayed, seizures become refractory to benzodiaze-
pines and other antiepileptic drugs (AEDs) [3–5]. This
pharmacoresistance increases as the internalization of synaptic
GABAAR, [6–8] and themigration of NMDAR and AMPAR toward synap-
ses progresses [9,10].
At present, we cannot block the seizure-associated acceleration of
receptor trafﬁcking, but we can block its consequences. If the receptor
trafﬁcking hypothesis is correct, this should reduce pharmacoresistance
and improve outcome.
It also suggests that the search for a better monotherapy may be fu-
tile, because it is unlikely to correct the maladaptive changes in both
GABA and glutamate networkswhich cause pharmacoresistance, unless
one practices “polytherapy with a single drug”. It also suggests that the
current practice ofwaiting for one drug to fail before trying the next one
[11] may give pharmacoresistance time to develop, and should be
reevaluated.
We tested these hypotheses in a model of SE induced by very high-
dose lithium and pilocarpine [12], and in a model of soman-induced SE
[13]. The results support the receptor trafﬁcking hypothesis. Methods
have been published [14,15] and will not be described in this brief
review.
2. Drug combinations based on the receptor trafﬁcking hypothesis
stop RSE seizures
2.1. Choice of drugs
The loss of synaptic GABAA receptors and the increase in synaptic
NMDAR and AMPAR induced by SE are proconvulsant andmaintain sei-
zure activity. Both need to be treated. Benzodiazepines penetrate the
brain rapidly and allosterically enhance the GABAAR response. They
are essential to the initial treatment of SE. Midazolam and diazepam
penetrate the brain more rapidly than lorazepam, and were selected
for that reason.
When treatment is delivered late, theremaynot be enoughGABAARs
left in synapses to fully restore inhibition, and an additional AED which
enhances inhibition at a nonbenzodiazepine site provides additional
beneﬁt [15]. The choice of the best AED for that purpose would require
toomuch space for this brief review. Valproate is one of several effective
candidate drugs and was used in of some of the experiments described
here.
Dizocilpine (MK-801), a selective ligand of theNMDAR channel, was
used in proof-of-principle experiments. Since it is too toxic for human
use, we also used ketamine, an NMDAR ligand which has additional
mechanisms of action [16], but is effective when injected iv or im [17],
and has a long record of safe human use. Since AMPAR changes are
NMDAR-dependent [10], use of an NMDAR blocker addresses both
AMPAR and NMDAR changes.
2.2. Results: pilocarpine-induced RSE
Dizocilpine monotherapy (1 mg/kg) reduced seizure number and
mortality, but did not terminate SE, cumulative seizure time, time to
the ﬁrst seizure-free minute, or Hjorth function [18], a measure of sei-
zure severity correlated to Electroencephalogram (EEG) power diaze-
pam monotherapy (5–20 mg/kg) reduced mortality but did not stop
SE, or reduce seizure number, time to the ﬁrst seizure-free minute, cu-
mulative seizure time, or Hjorth function. However, the combination
of diazepam with dizocilpine was very effective in stopping SE, elimi-
nating mortality and reducing SE duration over 100-fold compared to
the untreated and diazepam-treated groups (Fig. 1A).
The combination of low-dose ketamine (10 mg/kg) with moderate
dose diazepam (5 mg/kg) reduced the duration of SE six-fold, and the
number of seizures 9-fold compared to controls, diazepamPlease cite this article as: J. Niquet, L. Lumley, R. Baldwin, et al., Early polyth
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duced the delay to the ﬁrst seizure-free minute of EEG, Hjorth function,
and EEG power integral over the ﬁrst hour posttreatment. Hjorth func-
tion remained low 6 h posttreatment, indicating that seizures did not
recur. EEG power immediately before treatment was the same in all
groups [14].
2.3. Results: soman-induced SE
Rats treated with midazolam (3 mg/kg) 40 min after SE had greater
24-h survival compared to rats treatedwith saline orwith 1mg/kgmid-
azolam. EEG power integral increased in all GD-exposed rats during un-
treated SE. During the ﬁrst hour after treatment, midazolam or
ketamine monotherapy reduced EEG power compared to vehicle, but
by 6 h after exposure, there was no difference between these groups
(data not shown). Rats treatedwith 30mg/kg ketamine+ 3mg/kgmid-
azolam or with 30 mg/kg ketamine + 3 mg/kg midazolam + 90 mg/kg
valproic acid after 40 min of GD-induced SE had signiﬁcantly reduced
EEG power integral during the 1-h and the 6-h time periods after treat-
ment, compared to the midazolam monotherapy group.
3. Drug combinations based on the receptor trafﬁcking hypothesis
reduce the long-term consequences of RSE
3.1. Neuronal injury
After pilocarpine-induced refractory SE (RSE), no neuronal injury
was detected in any ketamine-treated animals in CA3 (Fig. 2A) or CA1
(Fig. 2B), suggesting anNMDAR-dependentmechanism of injury during
RSE in hippocampal pyramidal cells. Rats treated with the midazolam–
ketamine–valproate combination, which stopped RSE rapidly, showed
remarkable reduction of neuronal injury, but rats treated with triple-
dose ketamine alone, which did not terminate RSE, showed equally
good neuroprotection. Thus, this appeared to be related to the neuro-
protective properties of ketamine, rather than to the ability of NMDAR
antagonist-containing combinations to stop RSE. This suggests that the
early use of ketamine for neuroprotection, regardless of or in addition
to its ability to stop seizures, might be a useful strategy in RSE. This neu-
roprotection is remarkable because signs of neuronal injury have been
documented within 20 min of seizure onset [19], but is not universal.
Ketamine neuroprotection was less complete in dentate hilus [20],
conﬁrming that seizure-induced neuronal injury is both cell-type- and
seizure-model-speciﬁc.
A neuroprotective effect of the midazolam–ketamine combination
was observed 5 weeks after soman-induced SE in hippocampus, thala-
mus, lateral amygdala, and piriform cortex, while animals treated with
midazolam or ketamine alone had signiﬁcant neuronal loss in those
areas (personal communication).
3.2. Spontaneous recurrent seizures
Treatmentofpilocarpine-inducedRSEwith themidazolam+ketamine
combination prevented epileptogenesis. No rat treated with that combi-
nation displayed any spontaneous recurrent seizures (SRS) (dual ther-
apy: 0 SRS; n = 10; p b 0.0001 vs valproate controls). We did not
have an untreated SE group, because no rat in that group survived
long enough to be tested. All rats which received 270 mg/kg of
valproate, which increased long-term survival but did not alter the se-
verity of SE, developed SRS (4.6 ± 1 SRS per week; n = 7). Some rats
treated with double-dose ketamine or double-dose midazolam devel-
oped SRS (p b 0.05 vs dual therapy), but differences with dual therapy
were not signiﬁcant. We do not know to what extent these results re-
ﬂect a reduction in SE severity and duration versus a true
antiepileptogenic action (Fig. 2C).
After soman-induced SE, 83% of untreated rats (VEH) that survived
beyond 1 week developed SRS, as expected [21], versus 80% in theerapy for benzodiazepine-refractory status epilepticus, Epilepsy & Be-
ES HEALTHCARE SYSTEM from ClinicalKey.com by Elsevier on November 09, 2019.
n. Copyright ©2019. Elsevier Inc. All rights reserved.
Fig. 1. A. Response of high-dose lithium–pilocarpine RSE to monotherapy with the GABAAR agonist diazepam or the NMDAR antagonists dizocilpine or ketamine, and to combination
therapy with GABAAR agonist coupled with NMDAR antagonists. Cholinergic RSE was terminated by GABAAR agonist – NMDAR antagonist combinations, and failed to stop with
monotherapy, even at high dose (diazepam 20 mg/kg, not shown). Dz5: diazepam 5 mg/kg; MK1: dizocilpine 1 mg/kg; Ket 10: ketamine 10 mg/kg; Dz5 + MK1: diazepam 5 mg/kg
combined with dizocilpine 1 mg/kg; Dz5 + Ket 10: diazepam 5 mg/kg combined with ketamine 10 mg/kg. *, **, ***: p b 0.05, 0.01, or 0.001 compared to diazepam 5 mg/kg. #, ##: p b
0.05 or 0.01 compared to dizocilpine 1 mg/kg. $, $$, $$$: p, 0.05, 0.01, or 0.001 compared to ketamine 10 mg/kg. Values are median ± interquartile range. Kruskall–Wallis with Dunn's
multiple comparisons. B. Results of treating sc soman-induced SE with benzodiazepine monotherapy, with a GABAAR agonist-NMDAR antagonist combination, or with a GABAAR
agonist-NMDAR antagonist-AED combination, 40 min after seizure onset. EEG power before treatment (SE) was similar in all experimental groups. Treatment with midazolam
3 mg/kg (GD/MDZ/SAL) or with ketamine 30 mg/kg (not shown) reduced EEG power slightly compared to untreated animals. The midazolam 3 mg/kg/ketamine 30 mg/kg
combination (GD/MDZ/KET) and the midazolam 3 mg/kg/ketamine 30 mg/kg/valproic acid combination reduced the EEG power integral much better than midazolam or ketamine
monotherapy. ***p b 0.001; **p b 0.01; p b 0.05. Data shown are mean ± S.E.M. These results suggest that GABAAR agonist-NMDAR antagonist and GABAAR agonist-NMDAR
antagonist-AED combinations are efﬁcacious in reducing EEG seizure severity against soman-induced SE.
3J. Niquet et al. / Epilepsy & Behavior xxx (xxxx) xxxmidazolam-treated group and 75% in the ketamine-treated group, and
25% of rats treated with the midazolam–ketamine combination had
SRS (Fig. 2D). The latter was signiﬁcantly lower than the midazolam
monotherapy group (p b 0.05).
3.3. Spatial memory deﬁcits
In the pilocarpine-induced RSE model, SE-associated loss of spatial
memory in the Morris water maze [22] (Fig. 2E) was impaired in the
valproate group (n = 7) compared to sham (no SE) controls (n = 8).
In the acquisition test, the midazolam + ketamine group (n = 10)
was undistinguishable from sham (no SE) controls and performed bet-
ter than the valproate group (n= 7; p b 0.0001), the midazolam group
(n = 10; p b 0.05), and the ketamine group (n = 10; p b 0.01) by
Kruskal–Wallis/Dunnet testing [14].
In soman-induced SE (Fig. 2F), spatial memory deﬁcits were evident
in the groups treated with midazolam (GDMDZ) or ketamine
(KETMDZ) monotherapy, while rats treated with a combination ofPlease cite this article as: J. Niquet, L. Lumley, R. Baldwin, et al., Early polyth
havior, https://doi.org/10.1016/j.yebeh.2019.06.011
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from untreated, no SE controls (no GD).
These observations show that combining a GABAAR agonist and an
NMDAR antagonist reduces not only the severity of SE but also its
long-term consequences as well.
4. Drug combinations based on the receptor trafﬁcking hypothesis
are synergistic and have a high efﬁcacy/toxicity ratio
The efﬁcacy/toxicity ratio is the key to therapeutic success. If an in-
crease in therapeutic potency is matched by an increase in potency of
toxic adverse effects, nothing is gained. We build isobolograms
[23–25] for both seizure-reducing therapeutic efﬁcacy of drug combina-
tions based on the receptor-trafﬁcking hypothesis, and for their toxic
side effects (impairment of motor function and impairment of con-
sciousness). The results suggest that the midazolam–ketamine–
valproate combination potentiates the therapeutic response without
potentiating toxicity, so that the therapeutic index [26] is improved byerapy for benzodiazepine-refractory status epilepticus, Epilepsy & Be-
 HEALTHCARE SYSTEM from ClinicalKey.com by Elsevier on November 09, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 2. A. Untreated SE controls showed extensive neuronal injury in CA3, 48 h after SE. Animals treated with midazolam or valproate monotherapy showed no signiﬁcant reduction of
neuronal injury. Polytherapy with combinations of midazolam/ketamine or midazolam/ketamine/valproate at 40 min after seizure onset showed nearly complete protection from
neuronal injury, but so did ketamine monotherapy. *p b 0.05; **p b 0.01 by Kruskal–Wallis analysis followed by Dunn's test. From Niquet et al. [14]. B. Results in CA1 were similar to
CA3, with nearly complete neuroprotection in the polytherapy and in the ketamine monotherapy groups. In the dentate hilus (not shown), neuroprotection was less complete.
Neuronal injury measured by unbiased stereology showed only an approximately 50% reduction in Fluoro-Jade positive cells in all three treatment groups. C. Midazolam–ketamine
dual therapy reduces epileptogenesis. Graph showing the number of spontaneous recurrent seizures (SRS) per week, ≥6 weeks after high-dose lithium–pilocarpine SE. The group
treated with midazolam–ketamine dual therapy had no SRS. We used valproate monotherapy as our control group because of high mortality in the untreated control group. *p b 0.05,
**p b 0.01, and ****p b 0.0001 versus valproate (Kruskal–Wallis followed by Dunn's test). From Niquet et al. [14]. D. SRS after soman-induced SE. Treatment with the midazolam–
ketamine combination reduced the incidence of SRS during the ﬁrst 2 weeks after SE, compared to midazolam monotherapy (p b 0.05). E. Treatment of lithium–pilocarpine SE with
the midazolam–ketamine combination reduced behavioral deﬁcits. Performance in the Morris water maze (MWM) shows the latency to reach the hidden platform (y-axis) on each
testing day (x-axis). Acquisition was slower in the group treated with triple-dose midazolam monotherapy than in “no SE” controls. The group treated with midazolam+ ketamine +
valproate was indistinguishable from “no SE” controls. **p b 0.01 versus valproate 270 mg/kg (by Kruskal–Wallis followed by Dunn's test). Data are presented as mean ± standard
error of the mean (SEM). *p b 0.05 versus Mz4.5 + Ket45, **p b 0.01 versus Mz4.5 + Ket45, and ****p b 0.0001 versus Mz4.5 + Ket45 by two-way analysis of variance (ANOVA). From
Niquet et al. [14]. F. After sc soman SE, spatial memory acquisition in the MWM was slower in rats treated with midazolam or ketamine monotherapy than in animals treated with
combination therapy or in “no SE” controls.
4 J. Niquet et al. / Epilepsy & Behavior xxx (xxxx) xxxswitching from mono- to polytherapy. Fig. 1C shows that toxicity was
simply additive between the three drugs of the combination, while
the therapeutic response showed positive cooperativity between
drugs and was synergistic. As a result of that synergy, this three-drug
combination delivered a greater therapeutic response than monother-
apy for the same level of drug-induced toxicity. The mechanism of
that synergy is unknown, since the drugs involved have no known di-
rect interaction at the molecular level, and the effect is probably too
rapid to be due to pharmacokinetic interactions. This synergism was
powerful enough to overcomepharmacoresistance: thediazepam+ke-
tamine + valproate combination stopped seizures at subanesthetic
doses while anesthetic doses of diazepam (20 mg/kg) did not.
5. Drug combinations based on the receptor trafﬁcking hypothesis
are more effective at stopping RSE than clinical guideline-
recommended combinations of AEDs
5.1. Therapeutic efﬁcacy
We compared a drug combination based on the receptor trafﬁcking
hypothesis to a drug combination suggested by current evidence-basedPlease cite this article as: J. Niquet, L. Lumley, R. Baldwin, et al., Early polyth
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mend benzodiazepine monotherapy followed by an AED (e.g.,
fosphenytoin), then by another AED (e.g., valproate), or anesthesia
[11]. A combination of midazolam (3 mg/kg), fosphenytoin
(50mg/kg), and valproic acid (90mg/kg),which follows AES guidelines,
was far less effective at stopping RSE than the combination of midazo-
lam (3 mg/kg), ketamine (30 mg/kg), and valproic acid (90 mg/kg),
which targets seizure-induced changes in GABAA and glutamate recep-
tors. Drugs were delivered simultaneously in both groups, 40 min after
EEG seizure onset. The combination based on the receptor trafﬁcking
hypothesis was far more effective in reducing the number of posttreat-
ment seizures (Fig. 3A), the EEG power integral over the ﬁrst hour post-
treatment (Fig. 3B), the time needed for EEG amplitude to decline to
twice the preseizure baseline (Fig. 3C), and the number of posttreat-
ment spikes for 24 h (Fig. 3D) than the drug combination which
followed AES guidelines.
5.2. Relevance of doses used in rodents to clinical SE
Receptor properties are similar in both species, and benzodiazepine
pharmacoresistance has been observed clinically [2,27], but circuitryerapy for benzodiazepine-refractory status epilepticus, Epilepsy & Be-
ES HEALTHCARE SYSTEM from ClinicalKey.com by Elsevier on November 09, 2019.
n. Copyright ©2019. Elsevier Inc. All rights reserved.
Fig. 3. The midazolam–ketamine–valproate combination, which targets seizure-induced changes in GABAA and glutamate receptors, was more effective than the midazolam–
fosphenytoin–valproate combination, which follows American Epilepsy Society guidelines [11]. The graphs show the number of computer-detected seizures per 24 h (A), the ratio of
EEG power integral over the ﬁrst hour posttreatment to initial EEG power at baseline (B), the time needed to reach an EEG amplitude of twice the preseizure baseline (C), and the number
of computer-detected spikes per 24 h (D). The combination of 3 mg/kg midazolam, 30 mg/kg ketamine, and 90 mg/kg valproate (n = 10) was far more potent than the combination of
3 mg/kg midazolam, 50 mg/kg fosphenytoin, and 90 mg/kg valproate. *p b 0.05 or ***p b 0.001 by Mann–Whitney analysis. Fosphenytoin is expressed in phenytoin equivalents.
5J. Niquet et al. / Epilepsy & Behavior xxx (xxxx) xxxand brain size are quite different in rats and humans, and the heterogene-
ity of clinical SEmay limit the applicability of conclusions drawn fromany
animal model to clinical situations. However, this type of comparison is
routinely done in cancer chemotherapy. Oncology drugs are compared
across species of vastly different size by using body surface area rather
than body weight as a denominator, and this method is recommended
by the FDA (Food and Drug Administration) to estimate the initial
human dose in chemotherapy trials [28–31]. Comparing our 250–300 g
rats to 70 kg humans by thatmethod suggests that the doses of valproate,
fosphenytoin, and levetiracetam used in this study are at or below the
“human equivalent dose” (HED) derived from the clinical literature [1,
11,32], while the midazolam dose used is slightly higher than the HED
and the ketamine dose is higher than the HED [1] but is lower than the
dose used in patients with RSE who responded to ketamine [17].
6. Timing of drug delivery is key: early simultaneous use of drug
combinations is far more effective than sequential use of the same
drugs at the same dose
Standard practice in treating SE is sequential polytherapy, in which
we wait for the ﬁrst drug to fail before giving the second drug, and for
the second drug to fail before giving the third drug [11]. This has the ad-
vantage of minimizing drug delivery and drug toxicity in responders,
but the disadvantage of delaying delivery of the second drug by at
least 30 min, and delivery of the third drug by at least 1 h. A study of
prehospital treatment of SE [2] suggests that even a few minutes'
delay in treatment can result in differences in the likelihood of develop-
ing full-blown SE. In order to mimic clinical situations where drugs are
only injected after the previous treatment fails, we treated SE with the
same drugs at the same dose in two groups of rats. In one group, the
three drugs were injected simultaneously. In the second group, the sec-
ond drug was injected 30 min after the ﬁrst, and the third drug was de-
livered 30 min after the second drug (Fig. 4A). Simultaneous
polytherapy was far more effective than sequential polytherapy in re-
ducing the posttreatment EEG power integral during the ﬁrst hour
(Fig. 4B), or the ﬁrst 6 h after treatment; in reducing the time needed
for EEG amplitude to decline to twice the preseizure baseline (Fig. 4C)
and in reducing the number of posttreatment seizures (not shown).
By those measures, sequential polytherapy was not signiﬁcantlyPlease cite this article as: J. Niquet, L. Lumley, R. Baldwin, et al., Early polyth
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clinical experience where the second and third drugs used in sequential
polytherapy have a low success rate [27]. This difference in outcome is
compatible with increasing pharmacoresistance, associated with
seizure-induced increases in receptor trafﬁcking, during the delay be-
tween sequential drug injections. Fig. 3 conﬁrms that principle in the
treatment of experimental RSE.
7. Conclusions
Traditional treatments of SE fail to overcome pharmacoresistance
and lead to RSE in about 30% of patients, yet clinical guidelines continue
to rely on a very small number of empirical trials, and pay little attention
to pathophysiology. Our improving knowledge of the mechanisms of
seizure-induced pharmacoresistance should prompt us to question
this tradition. Status epilepticus triggers key changes in GABA and gluta-
mate receptors, yetwe continue to treat it with a single GABAergic drug,
leaving changes in excitatory networks untreated. We also continue to
delay administration of the second drug until the ﬁrst one has failed,
and administration of the third drug until the second one has failed, ig-
noring evidence that pharmacoresistance increases with time and with
seizure burden. Replacing a benzodiazepine (diazepam) with another
benzodiazepine with better pharmacokinetics (midazolam) is bound
to fail because it does not address the main reason for benzodiazepine
pharmacoresistance, which is the loss of synaptic GABAAR. Clinical trials
comparing monotherapies are bound to show only minor differences
between drugs, since each one treats only part of the problem.
We tested the hypothesis that decreases in synaptic GABAAR and in-
creases in synaptic glutamate receptors are key elements in the devel-
opment of pharmacoresistance and in the initiation and maintenance
of SE. Our results suggest that changes in both GABAA and glutamate
networks need to be treated to overcome seizure-induced
pharmacoresistance. In the treatment of RSE, drug combinations
which include a GABAAR agonist and a NMDAR antagonist are far
more effective at stopping seizures than higher-dose monotherapy, or
than other drug combinations, supporting a key role of GABAA and glu-
tamate receptor trafﬁcking in the pathophysiology of SE. This is true in
soman-induced SE as well. Drug combinations based on the receptor
trafﬁcking hypothesis not only terminate RSE, but also reduce or abolisherapy for benzodiazepine-refractory status epilepticus, Epilepsy & Be-
 HEALTHCARE SYSTEM from ClinicalKey.com by Elsevier on November 09, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 4. A. Experimental ﬂow: In the simultaneous group, the combination of midazolam 3 mg/kg, ketamine 30 mg/kg, and valproate 90 mg/kg was administered simultaneously 40 min
after seizure onset. In the sequential group, the same drugs at the same dose were injected 30min apart, starting 40min after seizure onset. B–C. The graphs show the ratio of EEG power
integral over the ﬁrst hour posttreatment to initial EEG power at baseline (B), and the time needed for EEG amplitude to decline to twice the preseizure baseline without EEG bursts (C),
indicating seizure termination. Simultaneous polytherapy (n=10)was far more effective than sequential monotherapies (n= 8–9) or higher-dosemidazolam (n= 10) in reducing EEG
power, and in stopping SE. * p b 0.05, * p b 0.05, ** p b 0.01, **** p b 0.0001 by ANOVA followed by Tukey's multiple comparison or by Kruskal–Wallis analysis followed by Dunn's test.
6 J. Niquet et al. / Epilepsy & Behavior xxx (xxxx) xxxsome of its long-term consequences: neuronal injury, spatial memory
deﬁcits, and epileptogenesis. Unlike benzodiazepines, they work when
treatment is delayed by 40 min after seizure onset. They show positive
cooperativity between drugs, so that their therapeutic index is im-
proved by their synergistic interaction.
We compared a drug combination inspired by the receptor trafﬁck-
ing hypothesis to a combination inspired by standard clinical guidelines.
Late treatment with the midazolam–ketamine–valproate combination
was more potent than the midazolam–fosphenytoin–valproate combi-
nation, showing that not all triple therapies show synergism, and sug-
gesting that simultaneously targeting GABAAR and glutamate receptor
changes is a valid therapeutic strategy. The simultaneous administra-
tion of the three drugs was far more efﬁcient in stopping seizures than
the standard practice of injecting the drugs sequentially, suggesting
that timing of treatment is essential, and that an early polytherapy
arm should be included in future clinical trials.
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